Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer Clinical Trial

Official title:
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Status Recruiting

Clinical Trial Summary

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05112991
Study type	Interventional
Source	3D Medicines
Contact	bin She
Phone	15973143911
Email	bin.she@3d-medicines.com
Status	Recruiting
Phase	Phase 2
Start date	March 4, 2022
Completion date	October 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04574284` - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Phase 2
Withdrawn	`NCT06046274` - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05106127` - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Phase 2
Completed	`NCT01289041` - BKM120 as Second-line Therapy for Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05077215` - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3
Recruiting	`NCT05481645` - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	Phase 2